Related Experiment Videos
Bromocriptine in Parkinson disease: further studies.
Neurology
|March 1, 1979
Summary
Bromocriptine, when added to levodopa/carbidopa, offers benefits for advanced Parkinson disease patients with worsening symptoms. While adverse effects occurred, it improved motor function and reduced "on-off" phenomena in many participants.
Area of Science:
- Neurology
- Pharmacology
Background:
- Advanced Parkinson disease (PD) presents challenges with levodopa/carbidopa treatment.
- Patients often experience increasing disability despite optimal dopaminergic therapy.
Purpose of the Study:
- To evaluate the efficacy and tolerability of bromocriptine as an adjunct therapy in advanced Parkinson disease.
- To assess bromocriptine's impact on motor symptoms and "on-off" fluctuations.
Main Methods:
- 66 patients with advanced PD and disability on levodopa/carbidopa received bromocriptine.
- Patients were assessed for motor symptom changes, "on-off" effects, and adverse events.
Main Results:
- 45 patients tolerated bromocriptine, showing significant improvement in rigidity, tremor, bradykinesia, and gait.
- 25 of these patients improved by at least one Hoehn and Yahr stage.
- Bromocriptine reduced "on-off" effects in 19 patients and allowed a 10% levodopa dose reduction.
Conclusions:
- Bromocriptine is a useful adjunct therapy for advanced Parkinson disease patients unresponsive to levodopa/carbidopa.
- Despite potential adverse effects, bromocriptine can improve motor function and reduce motor fluctuations.